|Articles|March 14, 2009

Drug Benefit Trends

  • Drug Benefit Trends Vol 21 No 3
  • Volume 21
  • Issue 3

Metabolic Agents Lead Drug Expenditures

Adults in the United States spent more on medications for diabetes and high cholesterol and other metabolic disorders than on any other class of medications in 2006. Expenditures for metabolic agents totaled $38.1 billion, or 18.3% of total outpatient drug expenditures for noninstitutionalized adults 18 years and older. In all, outpatient drug spending totaled $208.1 billion in 2006. Expenditures for the top 5 therapeutic classes accounted for $130.8 billion, or 62.9% of total expenditures. Findings are from the ongoing Medical Expenditure Panel Survey conducted by the Agency for Healthcare Research and Quality.

Adults in the United States spent more on medications for diabetes and high cholesterol and other metabolic disorders than on any other class of medications in 2006. Expenditures for metabolic agents totaled $38.1 billion, or 18.3% of total outpatient drug expenditures for noninstitutionalized adults 18 years and older. In all, outpatient drug spending totaled $208.1 billion in 2006. Expenditures for the top 5 therapeutic classes accounted for $130.8 billion, or 62.9% of total expenditures. Findings are from the ongoing Medical Expenditure Panel Survey conducted by the Agency for Healthcare Research and Quality.

After metabolic agents, the top-selling categories were cardiovascular agents, $33.1 billion, or 16%; CNS drugs (including analgesics), $28.2 billion, or 13.6%; psychotherapeutic agents, $17.5 billion, or 8.4%; and hormones, $14.0 billion, or 6.7% (Cover Figure). (Metabolic agents include diabetic supplies and equipment and also insulin, which in this survey is classified as a metabolic agent rather than as a hormone.)

Medications dispensed most often were CNS drugs. These were purchased by 45.5% of persons who had a prescription drug expense. Cardiovascular agents were purchased by 38.9%, hormones by 29.7%, and metabolic agents by 28.9%, while psychotherapeutic agents were purchased by 16.9%.

Internal server error